Trial Profile
A prospective study to evaluate the safety and efficacy of intravenous ferumoxytol (Feraheme) in patients with ST-elevation myocardial infarction (STEMI).
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 05 Dec 2015
Price :
$35
*
At a glance
- Drugs Ferumoxytol (Primary)
- Indications Myocardial infarction
- Focus Adverse reactions; Therapeutic Use
- Acronyms CMR
- 05 Dec 2015 New trial record